Describes leadership dilemmas facing the top management team of the leading Indian pharmaceutical companies - the first in its industry to be listed on the NYSE. Many admired for its impressive growth, Dr. Reddy's at a crossroads. How much attention should be placed on its legacy business of active pharmaceutical ingredients and generic drugs, which brought the company its current growth, and how much it should focus on the future of business as special drugs and the discovery of new chemical substances? Two represent different business models and cross-border strategy, organization and human resource requirements of each of them is a problem for the team of top Dr. Reddy. "Hide
by Bala Chakravarthy, Anand Jha Source: IMD 15 pages. Publication Date: January 1, 2003. Prod. #: IMD216-PDF-ENG
Related Case Solutions & Analyses:
The Broad Institute: Applying the Power of Genomics to Medicine
Starlite Corp.: General Information
Strategic Roads That Diverge or Converge: GM and Toyota in the Battle for the Top
Qualtrics: Scaling an Inside-Sales Organization
ENSURING THE SUCCESS OF YOUR STRATEGIC INITIATIVES
REVIEWING STRATEGY-EXECUTION CAPABILITIES
Wells Fargo: Solar Energy for Los Angeles Branches (B)
Brazil vs. the U.S. at the WTO: The U.S.-Brazil Cotton Subsidy Dispute
Kalamandir: Creating an Ecosystem for Livelihood Generation
Volvo and Geely
